Trevi Therapeutics, Inc. Banner Image

Trevi Therapeutics, Inc.

  • Ticker TRVI
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Trevi Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in New Haven, Connecticut
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Trevi is currently developing Haduvio for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’sMore disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of Haduvio, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
4.8 / 5.0 (189)

Trevi Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 189 reviews.

Trevi Therapeutics, Inc.

Most Recent Annual Report

Trevi Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Trevi Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!